VivoSeq
Other

Adjuvant Therapy

0

Pipeline Programs↗

30

Active Trials↗

4

Companies Involved↗

Adjuvant Therapy is an early-stage landscape with 0 programs across 4 companies. The most active players are Betta Pharmaceuticals Co., Ltd., Cytocraft Biopharmaceutical Co., Ltd., Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

41/100

Pipeline Velocity

22/100

Mech. Concentration

N/A

Completion Rate

46/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

B

Betta Pharmaceuticals Co., Ltd.

0 programs

PreclinicalC

Cytocraft Biopharmaceutical Co., Ltd.

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalN

Nanjing Sanhome Pharmaceutical, Co., Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

66

clinical trials

Unknown status23 · 35%
Recruiting19 · 29%
Completed6 · 9%
Not yet recruiting6 · 9%
Active, not recruiting5 · 8%
Terminated4 · 6%
Other3 · 5%

Clinical Trials

Trial Activity

66 trials

PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC
Recruiting·GGuangdong Provincial People's Hospital·Phase 3·NCT06533384·310 enrolled
Enhanced Adjuvant Therapy for Newly Diagnosed GBM With Partial Surgical Resection or Short-term Progression
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT06936046·200 enrolled
A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection
Recruiting·—·Phase 2·NCT05407519·40 enrolled
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Recruiting·NNuvation Bio Inc.·Phase 3·NCT07154706·180 enrolled
A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients
Recruiting·SSun Yat-sen University·Phase 3·NCT03561740·794 enrolled
Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis
Recruiting·AAHS Cancer Control Alberta·Phase 2·NCT06860542·94 enrolled
Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC
Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06939127·38 enrolled
Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC
Recruiting·SSun Yat-sen University·N/A·NCT06609876·108 enrolled
Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
Recruiting·FFudan University·Phase 3·NCT05909332·764 enrolled
Tumor Regression Grade As Predictor of Adjuvant Therapy
Recruiting·FFujian Medical University Union Hospital·N/A·NCT06710665·400 enrolled
Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC
Recruiting·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT06081673·72 enrolled
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
Recruiting·—·Phase 2·NCT06863311·70 enrolled
A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
Recruiting·AAkeso·Phase 3·NCT05489289·570 enrolled
A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC
Recruiting·ZZhejiang Cancer Hospital·Phase 2·NCT06190639·31 enrolled
SDTM001 Injection as Adjuvant Therapy for NSCLC Patients After Radical Surgical Resection
Recruiting·CCytocraft Biopharmaceutical Co., Ltd.·Phase 1·NCT07096882·22 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)